PacBio provides the most accurate long-read sequencing solutions with a strong commitment to the uncompromising pursuit of high-fidelity genomic data.1
Omniome is a biotechnology company developing a highly differentiated and accurate short-read sequencing platform with the potential to advance cancer diagnostics, drive higher fidelity for single-cell applications, and broadly enable clinical sequencing.
Our combined teams and technology will offer a broad suite of solutions with a differentiated offering focused on value for high-growth clinical markets, and more.
Our mission is to enable the promise of genomics to better human health
Our teams operate with one guiding principle — the status quo is simply not good enough when it comes to the future of genomics. With Omniome, we hope to further enable:
Our focus on differentiated technology gives customers greater flexibility in applications where accuracy matters.
With long- and short-read sequencing, PacBio and Omniome’s combined portfolio paves the way to address a diverse set of applications, including but not limited to:
The completion of this acquisition adds a new presence for PacBio in San Diego. Building on the deep expertise of the PacBio team in our Bay Area global headquarters, this close expands our footprint and establishes an additional center of excellence for our growing family.
We have over 100 openings available in multiple locations throughout the U.S. and remote.
We're looking for talented, passionate individuals to join us. Interested in changing the world?
Yes. See our press release.
Omniome is a San Diego-based biotechnology company developing a proprietary and highly differentiated short-read sequencing platform capable of delivering increased sequencing accuracy.
It is Omniome's mission to collaborate with the scientific community to deliver the world's most trusted short-read sequencing platform. To inquire about collaborations, please submit your interest here: https://www.omniome.com/contact/.
PacBio will remain steadfast and focused on delivering the world’s most advanced sequencing technologies and services. We are continuing to develop further improvements to HiFi and the Sequel IIe platform. We believe both HiFi and Omniome will address different scientific questions.
Our current plan is to continue to expand our Bay Area global headquarters, while also building and expanding our presence in San Diego. In this way, we will have access to two of the greatest genomics talent centers. Omniome employees will continue to work from their existing offices.